Alan Sandler

43.1k total citations · 9 hit papers
163 papers, 23.8k citations indexed

About

Alan Sandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alan Sandler has authored 163 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Alan Sandler's work include Lung Cancer Treatments and Mutations (91 papers), Lung Cancer Research Studies (57 papers) and Colorectal Cancer Treatments and Studies (36 papers). Alan Sandler is often cited by papers focused on Lung Cancer Treatments and Mutations (91 papers), Lung Cancer Research Studies (57 papers) and Colorectal Cancer Treatments and Studies (36 papers). Alan Sandler collaborates with scholars based in United States, Spain and France. Alan Sandler's co-authors include Joan H. Schiller, Chandra P. Belani, David H. Johnson, David H. Johnson, Julie R. Brahmer, Robert J. Gray, Afshin Dowlati, Michael C. Perry, Rogério Lilenbaum and Corey J. Langer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Alan Sandler

161 papers receiving 23.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 4.5k citations Alan Sandler, Robert J. Gray et al. profile →
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 4.1k citations Joan H. Schiller, Chandra P. Belani et al. profile →
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2018 2.6k citations Federico Cappuzzo, Francesco Orlandi et al. profile →
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 2.1k citations Roy S. Herbst, Chandra P. Belani et al. profile →
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Alexander I. Spira, Marcus Ballinger et al. profile →
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, L. Fehrenbacher et al. profile →
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 500 citations Corey J. Langer, Lawrence H. Einhorn et al. profile →
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

2020 405 citations Federico Cappuzzo, Maen Hussein et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Alan Sandler

Since Specialization

Citations

This map shows the geographic impact of Alan Sandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Sandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Sandler more than expected).

Fields of papers citing papers by Alan Sandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Sandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Sandler. The network helps show where Alan Sandler may publish in the future.

Co-authorship network of co-authors of Alan Sandler

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Sandler. A scholar is included among the top collaborators of Alan Sandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Sandler. Alan Sandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients 2021 ·PLoS ONE ·Namrata S. Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger, Susan Flynn, Marcin Kowanetz, Priti S. Hegde	7
2	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial breakdown → 2019 ·The Lancet Oncology ·Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo	1137
3	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics 2018 ·Clinical Cancer Research ·Laurent Claret, Jin Y. Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, D. Gandara, Jean‐Charles Soria, René Bruno	53
4	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC 2018 ·Journal of Thoracic Oncology ·David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi	114
5	Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria 2018 ·Journal of Thoracic Oncology ·Philip Bonomi, Gideon M. Blumenthal, Andrea Stern Ferris, David J. Stewart, Wendy Selig, Lee M. Krug, Jeff Allen, Gwynn Ison, Corey J. Langer, Allen S. Melemed, Lauretta Odogwu, Upal Roy, Alan Sandler	10
6	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study 2018 ·Lung Cancer ·Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pawel, Carol O’Hear, (unknown), Sylvia Hu, Marcus Ballinger, Alan Sandler, Mayank Gandhi, L. Fehrenbacher	132
7	OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC 2018 ·Journal of Thoracic Oncology ·Vassiliki A. Papadimitrakopoulou, Manuel Cobo, Rodolfo Bordoni, Pascale Dubray‐Longeras, Zsuzsanna Szalai, (unknown), Silvia Novello, Francesco Orlandi, S. Ball, Jerome H. Goldschmidt, Rachel E. Sanborn, Tien Hoang, Diana Mendus, Yu Deng, Marcin Kowanetz, (unknown), Wei Lin, Alan Sandler, Makoto Nishio	102
8	P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC 2017 ·Journal of Thoracic Oncology ·Heather A. Wakelee, Nasser K. Altorki, Eric Vallières, Caicun Zhou, (unknown), Michael F. Howland, Fan Xia, Tien Hoang, Alan Sandler, Enriqueta Felip	2
9	Prospects and progress of atezolizumab in non-small cell lung cancer 2017 ·Expert Opinion on Biological Therapy ·Johan Vansteenkiste, Els Wauters, Keunchil Park, Achim Rittmeyer, Alan Sandler, Alexander I. Spira	12
10	PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study 2016 ·Journal of Thoracic Oncology ·Michael S. Gordon, Roy S. Herbst, Leora Horn, Jean‐Charles Soria, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott Antonia, Ani Sarkis Balmanoukian, Philippe A. Cassier, Bo Liu, Marcin Kowanetz, Carol O’Hear, Marcella Fassò, Alan Sandler, Scott Gettinger	2
11	PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC 2016 ·Journal of Thoracic Oncology ·Eric Vallières, Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, (unknown), Michael F. Howland, Fan Xia, Tien Hoang, Alan Sandler, Heather A. Wakelee	2
12	Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials 2012 ·Clinical Lung Cancer ·Leora Horn, Vicki L. Keedy, Norma Campbell, (unknown), (unknown), (unknown), David P. Carbone, Alan Sandler, David H. Johnson	26
13	Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 2010 ·Journal of Thoracic Oncology ·Julie R. Brahmer, Suzanne E. Dahlberg, Robert J. Gray, Joan H. Schiller, Michael C. Perry, Alan Sandler, David H. Johnson	51
14	Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Alan Sandler, Jing Yi, Suzanne E. Dahlberg, Margaret Kolb, Lisa Wang, Julie Hambleton, Joan H. Schiller, David H. Johnson	125
15	Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors 2007 ·Molecular Cancer Therapeutics ·Mace L. Rothenberg, Elizabeth Poplin, Alan Sandler, (unknown), Floyd E. Fox, (unknown), (unknown), Hagop Youssoufian	17
16	PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study 2007 ·Journal of Thoracic Oncology ·Suresh S. Ramalingam, Suzanne E. Dahlberg, Corey J. Langer, Robert J. Gray, Chandra P. Belani, Julie R. Brahmer, Alan Sandler, Joan H. Schiller, David H. Johnson	1
17	PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·George R. Blumenschein, Alan Sandler, Timothy J. O’Rourke, Jesse McGreivy, Yu‐Nien Sun, Yining Ye, (unknown), Joe Stephenson	7
18	Irinotecan therapy for small-cell lung cancer. 2002 ·PubMed ·Alan Sandler	10
19	Paclitaxel Plus Gallium Nitrate and Filgrastim in Patients With Refractory Malignancies 1998 ·American Journal of Clinical Oncology ·Alan Sandler, Susan Fox, (unknown), (unknown), George Weber, R Gonin, Patrick J. Loehrer, Lawrence H. Einhorn, Robert Dreicer	8
20	Workshop on How to Perform Clinical Outcome Studies 1997 ·Anesthesiology ·Denise J. Wedel, Paul F. White, Timothy J. Brennan, Alan Sandler	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact